Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab in High-risk Smoldering Multiple Myeloma (SMM)
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).